Cited by 318Epilepsy research and treatmentNeuroscience and Neuropharmacology ResearchPharmacological Effects and Toxicity Studies

The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.

Antiepileptic Drugs in Non-Epilepsy Disorders: Relations between Mechanisms of Action and Clinical Efficacy

Johannessen Landmark, Cecilie·2008·CNS Drugs

DOI 10.2165/00023210-200822010-00003

Open this paper in CoChat — free account

Abstract

Antiepileptic drugs (AEDs) are used extensively to treat multiple non-epilepsy disorders, both in neurology and psychiatry. This article provides a review of the clinical efficacy of AEDs in non-epilepsy disorders based on recently published preclinical and clinical studies, and attempts to relate this efficacy to the mechanism of action of AEDs and pathophysiological processes associated with the disorders. Some newer indications for AEDs have been established, while others are under investigation. The disorders where AEDs have been demonstrated to be of clinical importance include neurological disorders, such as essential tremor, neuropathic pain and migraine, and psychiatric disorders, including anxiety, schizophrenia and bipolar disorder. Many of the AEDs have various targets of action in the synapse and have several proposed relevant mechanisms of action in epilepsy and in other disorders. Pathophysiological processes disturb neuronal excitability by modulating ion channels, receptors and intracellular signalling pathways, and these are targets for the pharmacological action of various AEDs. Attention is focused on the glutamatergic and GABAergic synapses. In psychiatric conditions such as schizophrenia and bipolar disorder, AEDs such as valproate, carbamazepine and lamotrigine appear to have clear roles based on their effect on intracellular pathways. On the other hand, some AEDs, e.g. topiramate, have efficacy for nonpsychiatric disorders including migraine, possibly by enhancing GABAergic and reducing glutamatergic neurotransmission. AEDs that seem to enhance GABAergic neurotransmission, e.g. tiagabine, valproate, gabapentin and possibly levetiracetam, may have a role in treating neurological disorders such as essential tremor, or anxiety disorders. AEDs with effects on voltage-gated sodium or calcium channels may be advantageous in treating neuropathic pain, e.g. gabapentin, pregabalin, carbamazepine, oxcarbazepine, lamotrigine and valproate. Co-morbid conditions associated with epilepsy, such as mood disorders and migraine, may often respond to treatment with AEDs. Other possible disorders where AEDs may be of clinical importance include cancer, HIV infection, drug and alcohol abuse, and also in neuroprotection. A future challenge is to evaluate the second-generation AEDs in non-epilepsy disorders and to design clinical trials to study their effects in such disorders in paediatric patients. Differentiation between the main mechanisms of action of the AEDs needs more consideration in drug selection for tailored treatment of the various non-epilepsy disorders.

Integrity signals

Registry

Crossref · 10.2165/00023210-200822010-00003

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Göttlicher, M., Minucci, S., Zhu, P., Krämer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Coco, F. L., Nervi, C., Pelicci, P. G., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,930
Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Algorithm for neuropathic pain treatment: An evidence based proposal
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005) · Pain · doi:10.1016/j.pain.2005.08.013 · Cited by 1,337
The neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1430 · Cited by 1,243
Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.
Akbarian, S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160008002 · Cited by 1,002
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
An astrocytic basis of epilepsy
Tian, G.-F., Azmi, H., Takano, T., Xu, Q., Peng, W., Lin, J., Oberheim, N., Lou, N., Wang, X., Zielke, H. R., et al. (2005) · Nature Medicine · doi:10.1038/nm1277 · Cited by 806
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Anticonvulsant drugs for management of pain: a systematic review
McQuay, H., Carroll, D., Jadad, A. R., Wiffen, P. J., & Moore, A. (1995) · BMJ · doi:10.1136/bmj.311.7012.1047 · Cited by 712

Show all 157 references

Research works printed but not linked: 14

Lydiard, 2003, J Clin Psychiatry, 64, 21
Nemeroff, 2003, Psychopharmacol Bull, 37, 133
Kralic, 2005, J Clin Invest, 115, 584, 10.1172/JCI200523625 · DOI
Chetcuti, 2005, Int J Neuropsychopharmacol, 28, 1
Keck, 2005, JClin Psychiatry, 67, 8
Premkumar, 2006, Cochrane Database Syst Rev, &NA;, CD005962
Drake, 2001, Cephalalgia, 21, 373
Krusz, 2001, Cephalalgia, 21, 373
Keck, 1993, J Clin Psychiatry, 54, 305
Manji, 2001, Psychopharmacol Bull, 35, 5
Owens, 2003, Psychopharmacol Bull, 37, 17
Henry, 2003, Psychopharmacol Bull, 37, 5
Myrick, 2003, Prim Psychiatry, 10, 59
De Paulis, 2003, Curr Opin Invest Drug, 4, 863

Sorted by citations

Consensus Paper: Pathological Role of the Cerebellum in Autism
Fatemi, S. H., Aldinger, K. A., Ashwood, P., Bauman, M. L., Blaha, C. D., Blatt, G. J., Chauhan, A., Chauhan, V., Dager, S. R., Dickson, P. E., et al. (2012) · The Cerebellum · doi:10.1007/s12311-012-0355-9 · Cited by 723
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Swarm, R. A., Paice, J. A., Anghelescu, D. L., Are, M., Bruce, J. Y., Buga, S., Chwistek, M., Cleeland, C. S., Craig, D. S., Gafford, E. F., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0038 · Cited by 641
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 529
Antiepileptic drug interactions—Principles and clinical implications
I. Johannessen, S., & Johannessen Landmark, C. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246254 · Cited by 343
Adult Cancer Pain
Swarm, R. A., Abernethy, A. P., Anghelescu, D. L., Benedetti, C., Blinderman, C. D., Boston, B., Cleeland, C. S., Coyle, N., deLeon-Casasola, O. A., Eilers, J., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0076 · Cited by 333
Common brain mechanisms of chronic pain and addiction
Elman, I., & Borsook, D. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.027 · Cited by 303
The management of cancer pain
Paice, J. A., & Ferrell, B. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20112 · Cited by 247
Anticonvulsant Medications and the Risk of Suicide, Attempted Suicide, or Violent Death
Patorno, E. (2010) · JAMA · doi:10.1001/jama.2010.410 · Cited by 243
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders
Chiu, C., & Chuang, D. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.006 · Cited by 232
Pain and suicidality: Insights from reward and addiction neuroscience
Elman, I., Borsook, D., & Volkow, N. D. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.003 · Cited by 226
The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trials
Zaccara, G., Gangemi, P. F., Perucca, P., & Specchio, L. M. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02966.x · Cited by 216
Depression and anxiety in children and adolescents with epilepsy: Prevalence, risk factors, and treatment
Ekinci, O., Titus, J. B., Rodopman, A. A., Berkem, M., & Trevathan, E. (2009) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2008.08.015 · Cited by 186
CACNA1C (rs1006737) is associated with schizophrenia
Nyegaard, M., Demontis, D., Foldager, L., Hedemand, A., Flint, T. J., Sørensen, K. M., Andersen, P. S., Nordentoft, M., Werge, T., Pedersen, C. B., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.69 · Cited by 182
Why are antiepileptic drugs used for nonepileptic conditions?
Bialer, M. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03712.x · Cited by 176
Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development
Wahab, A. (2010) · Pharmaceuticals · doi:10.3390/ph3072090 · Cited by 160
Metabolic and endocrine effects of valproic acid chronic treatment
Belcastro, V., D’Egidio, C., Striano, P., & Verrotti, A. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2013.08.016 · Cited by 149
Target Identification for CNS Diseases by Transcriptional Profiling
Altar, C. A., Vawter, M. P., & Ginsberg, S. D. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.172 · Cited by 139
Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis
Tsiropoulos, I., Andersen, M. T., & Hallas, J. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1736 · Cited by 138
Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications
Krasowski, M. D. (2010) · Pharmaceuticals · doi:10.3390/ph3061908 · Cited by 133
Topiramate-induced weight loss: A review
Verrotti, A., Scaparrotta, A., Agostinelli, S., Pillo, S. D., Chiarelli, F., & Grosso, S. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.05.014 · Cited by 124
Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population
Landmark, C. J., Fossmark, H., Larsson, P. G., Rytter, E., & Johannessen, S. I. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.02.012 · Cited by 123
A systematic review of population pharmacokinetics of valproic acid
Methaneethorn, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13510 · Cited by 115
Antiepileptic drugs in epilepsy and other disorders—A population-based study of prescriptions
Landmark, C. J., Larsson, P. G., Rytter, E., & Johannessen, S. I. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.07.005 · Cited by 111
Host factors affecting antiepileptic drug delivery—Pharmacokinetic variability
Landmark, C. J., Johannessen, S. I., & Tomson, T. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.003 · Cited by 110
Epigenetic mechanisms in migraine: a promising avenue?
Eising, E., Datson, N. A., van den Maagdenberg, A. M. J. M., & Ferrari, M. D. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-26 · Cited by 112
Association between use of antiepileptic drugs and fracture risk: A systematic review and meta-analysis
Shen, C., Chen, F., Zhang, Y., Guo, Y. C., & Ding, M. (2014) · Bone · doi:10.1016/j.bone.2014.04.018 · Cited by 111
The Long-Term Safety of Antiepileptic Drugs
Gaitatzis, A., & Sander, J. W. A. S. (2013) · CNS Drugs · doi:10.1007/s40263-013-0063-0 · Cited by 108
Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial
Narula, P. K., Rehan, H. S., Unni, K. E. S., & Gupta, N. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.001 · Cited by 105
Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders
Patsalos, P. N. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0088-z · Cited by 103
Seizure and Epilepsy: Studies of Seizure Disorders in Drosophila
Parker, L., Howlett, I. C., Rusan, Z. M., & Tanouye, M. A. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-387003-2.00001-x · Cited by 103
Drugs that Disturb Sleep and Wakefulness
Schweitzer, P. K., & Randazzo, A. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-24288-2.00045-3 · Cited by 101
Valproic Acid Phase Shifts the Rhythmic Expression of PERIOD2::LUCIFERASE
Johansson, A.-S., Brask, J., Owe-Larsson, B., Hetta, J., & Lundkvist, G. B. S. (2011) · Journal of Biological Rhythms · doi:10.1177/0748730411419775 · Cited by 97
Antiepileptic drugs in the treatment of psychiatric disorders
Kaufman, K. R. (2011) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2011.03.011 · Cited by 98
Role of Antiepileptic Drugs in the Management of Eating Disorders
McElroy, S. L., Guerdjikova, A. I., Martens, B. E., Keck, P. E., Pope, H. G., & Hudson, J. I. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00004 · Cited by 95
Antiepileptic drug monotherapy versus polytherapy
Stephen, L. J., & Brodie, M. J. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328350ba68 · Cited by 90
The adverse event profile of lacosamide: A systematic review and meta‐analysis of randomized controlled trials
Zaccara, G., Perucca, P., Loiacono, G., Giovannelli, F., & Verrotti, A. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03589.x · Cited by 89
Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?
Citrome, L. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.9.1.55 · Cited by 86
Topiramate and cognitive impairment: evidence and clinical implications
Mula, M. (2012) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098612455357 · Cited by 84
Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression
Rossi, L. E., Avila, D. E., Spallanzani, R. G., Ziblat, A., Fuertes, M. B., Lapyckyj, L., Croci, D. O., Rabinovich, G. A., Domaica, C. I., & Zwirner, N. W. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0711339 · Cited by 83
Changes in the anti-oxidant system in adult epilepsy patients receiving anti-epileptic drugs
Işık, M., Demir, Y., Kırıcı, M., Demir, R., Şimşek, F., & Beydemir, Ş. (2015) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2015.1026912 · Cited by 81
Weight-Reducing Side Effects of the Antiepileptic Agents Topiramate and Zonisamide
Antel, J., & Hebebrand, J. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_20 · Cited by 79
The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection
Verrotti, A., Tambucci, R., Francesco, L. D., Pavone, P., Iapadre, G., Altobelli, E., Matricardi, S., Farello, G., & Belcastro, V. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1707668 · Cited by 79
Bone loss associated with use of antiepileptic drugs
Nakken, K. O., & Taubøll, E. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003636475 · Cited by 77
Interactions between antiepileptics and second-generation antipsychotics
de León, J., Santoro, V., D’Arrigo, C., & Spina, E. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.660918 · Cited by 79
Psychiatric comorbidity in patients with epilepsy: a population-based study
Karouni, M., Arulthas, S., Larsson, P. G., Rytter, E., Johannessen, S. I., & Landmark, C. J. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0861-y · Cited by 77
Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity
Sommer, B. R., Mitchell, E. L., & Wroolie, T. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613481257 · Cited by 76
Voltage-Gated Sodium Channels: Structure, Function, and Pathophysiology
Catterall, W. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-378630-2.00208-5 · Cited by 74
Advances in anti-epileptic drug testing
Krasowski, M. D., & McMillin, G. A. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.06.002 · Cited by 71
Pharmacologic Treatments for Binge-Eating Disorder
McElroy, S. L. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.sh16003su1c.03 · Cited by 69
The Nervous System and Metabolic Dysregulation: Emerging Evidence Converges on Ketogenic Diet Therapy
Ruskin, D. N., & Masino, S. A. (2012) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00033 · Cited by 67
The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis
Taylor, S. F., Grove, T. B., Ellingrod, V. L., & Tso, I. F. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz046 · Cited by 67
Effects of vitamin U (S-methyl methionine sulphonium chloride) on valproic acid induced liver injury in rats
Sökmen, B. B., Tunalı, S., & Yanardağ, R. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.07.056 · Cited by 67
A larval zebrafish model of bipolar disorder as a screening platform for neuro-therapeutics
Ellis, L. D., & Soanes, K. H. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.05.043 · Cited by 65
Pharmacological Management of Epilepsy
Landmark, C. J., & Johannessen, S. I. (2008) · Drugs · doi:10.2165/00003495-200868140-00001 · Cited by 63
ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain
D’Amico, R., Impellizzeri, D., Cuzzocrea, S., & Paola, R. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155330 · Cited by 64
Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives
Chang, S.-C., Goh, K. K., & Lu, M. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i10.696 · Cited by 72
Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review
Arbaizar, B., Gómez‐Acebo, I., & Llorca, J. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2008.02.002 · Cited by 61
Value of therapeutic drug monitoring in epilepsy
Johannessen, S. I., & Landmark, C. J. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.6.929 · Cited by 61
Proconvulsant effects of antidepressants — What is the current evidence?
Landmark, C. J., Henning, O. J., & Johannessen, S. I. (2016) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.01.029 · Cited by 62
Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants
Italiano, D., Spina, E., & de León, J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.956081 · Cited by 60
Evidence-based guidelines for the pharmacological treatment of migraine
Ornello, R., Caponnetto, V., Ahmed, F., Al‐Khazali, H. M., Ambrosini, A., Ashina, S., Baraldi, C., Bellotti, A., Brighina, F., Calabresi, P., et al. (2025) · Cephalalgia · doi:10.1177/03331024241305381 · Cited by 65
Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)
Korczyn, A. D., Schachter, S. C., Brodie, M. J., Dalal, S. S., Engel, J., Guekht, A. B., Hečimović, H., Jerbi, K., Kanner, A. M., Landmark, C. J., et al. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.03.012 · Cited by 57
Augmentation of atypical antipsychotics with valproic acid. An open‐label study for most difficult patients with schizophrenia
Suzuki, T., Uchida, H., Takeuchi, H., Nakajima, S., Nomura, K., Tanabe, A., Yagi, G., Watanabe, K., & Kashima, H. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1073 · Cited by 57
From ion channels to complex networks: Magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy
Bianchi, M. T., Pathmanathan, J. S., & Cash, S. S. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.09.049 · Cited by 56
Non-Hormonal Treatment Strategies for Vasomotor Symptoms
Hall, E., Frey, B. N., & Soares, C. N. (2011) · Drugs · doi:10.2165/11585360-000000000-00000 · Cited by 56
Is an “Epigenetic Diet” for Migraines Justified? The Case of Folate and DNA Methylation
Fila, M., Chojnacki, C. J., Chojnacki, J., & Błasiak, J. (2019) · Nutrients · doi:10.3390/nu11112763 · Cited by 57
Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders—a pharmacoepidemiological study and clinical implications
Baftiu, A., Landmark, C. J., Rusten, I. R., Feet, S. A., Johannessen, S. I., & Larsson, P. G. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2092-3 · Cited by 55
HDACi
Duncan, H. F., Smith, A. J., Fleming, G. J. P., & Cooper, P. R. (2011) · Journal of Dental Research · doi:10.1177/0022034511406919 · Cited by 52
Chemometrics enhanced HPLC–DAD performance for rapid quantification of carbamazepine and phenobarbital in human serum samples
Vosough, M., Ghafghazi, S., & Sabetkasaei, M. (2013) · Talanta · doi:10.1016/j.talanta.2013.10.026 · Cited by 49
A Randomized, Controlled, Double-Blinded Clinical Trial of Gabapentin 300mg versus 900mg versus Placebo for Anxiety Symptoms in Breast Cancer Survivors
Lavigne, J., Heckler, C., Mathews, J., Palesh, O., Kirshner, J., Lord, R. S., Jacobs, A., Amos, E., Morrow, G., & Mustian, K. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2251-x · Cited by 49
Antiepileptic drugs in Australia: 2002–2007
Hollingworth, S., & Eadie, M. J. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1871 · Cited by 47
Effects of acute and chronic treatment elicited by lamotrigine on behavior, energy metabolism, neurotrophins and signaling cascades in rats
Abelaira, H. M., Réus, G. Z., Ribeiro, K. F., Zappellini, G., Ferreira, G. K., Gomes, L. M., Carvalho‐Silva, M., Luciano, T. F., Marques, S. D. O., STRECK, E. L., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.10.007 · Cited by 46
Valproic Acid–Induced Coagulopathy
Kumar, R., Vidaurre, J. A., & Gedela, S. (2019) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.04.019 · Cited by 47
The antihyperalgesic effect of levetiracetam in an inflammatory model of pain in rats: mechanism of action
Micov, A. M., Tomic´, M. A., Popović, B. V., & Stepanović-Petrović, R. M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00877.x · Cited by 46
Valproate prescriptions for nonepilepsy disorders in reproductive‐age women
Adedinsewo, D. A., Thurman, D. J., Luo, Y., Williamson, R. S., Odewole, O. A., & Oakley, G. P. (2013) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.23147 · Cited by 46
Neurological comorbidity and epilepsy: implications for treatment
Zaccara, G. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01146.x · Cited by 45
Antiepileptic drugs for central post-stroke pain management
Siniscalchi, A., Gallelli, L., Sarro, G. D., Malferrari, G., & Santangelo, E. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.003 · Cited by 44
Prevalence, clinical features and potential therapies for fibromyalgia in primary headaches
de Tommaso, M. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.190 · Cited by 44
Systems biology, complexity, and the impact on antiepileptic drug discovery
Margineanu, D. G. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.08.029 · Cited by 43
Epilepsy and intellectual disability: Does epilepsy increase the likelihood of co-morbid psychopathology?
Arshad, S., Winterhalder, R., Underwood, L., Kelesidi, K., Chaplin, E., Kravariti, E., Anagnostopoulos, D., Bouras, N., McCarthy, J. M., & Tsakanikos, E. (2010) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2010.10.013 · Cited by 42
A review on antiepileptic drugs-dependent fatigue: Pathophysiological mechanisms and incidence
Siniscalchi, A., Gallelli, L., Russo, E., & Sarro, G. D. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.013 · Cited by 42
Treatment initiation in epilepsy: An expert consensus in Spain
Villanueva, V., Álvarez, J. C. S., Peña, P., Salas‐Puig, J., Martínez, F. C., & Gil‐Nagel, A. (2010) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2010.07.016 · Cited by 41
Comparison of the Effectiveness of Topiramate and Sodium Valproate in Pediatric Migraine
Ünalp, A., Uran, N., & Öztürk, A. (2008) · Journal of Child Neurology · doi:10.1177/0883073808318547 · Cited by 41
Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials.
Goh, K. K., Chen, C.-H., & Lu, M.-L. (2019) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2018.1449864 · Cited by 40
Augmentation With Pregabalin in Schizophrenia
Englisch, S., Eer, A., Enning, F., Hohmann, S., Schanz, H., & Zink, M. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e5c095 · Cited by 40
Carbamazepine Alleviates Retinal and Optic Nerve Neural Degeneration in Diabetic Mice via Nerve Growth Factor-Induced PI3K/Akt/mTOR Activation
Elsherbiny, N. M., Abdel–Mottaleb, Y., Elkazaz, A. Y., Atef, H., Lashine, R. M., Youssef, A. M., Morsy, W. E., El-Ghaiesh, S. H., Elshaer, R. E., El‐Shafey, M., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01089 · Cited by 40
Prior Authorization for Antidepressants in Medicaid
Adams, A. S., Zhang, F., LeCates, R. F., Graves, A. J., Ross‐Degnan, D., Gilden, D., McLaughlin, T. J., Lu, C. Y., Trinacty, C. M., & Soumerai, S. B. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.39 · Cited by 39
Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release
Werz, M. A. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3343 · Cited by 39
Antiepileptic use for epilepsy and nonepilepsy disorders
Leong, C., Mamdani, M., Gomes, T., Juurlink, D. N., Macdonald, E. M., & Yogendran, M. S. (2016) · Neurology · doi:10.1212/wnl.0000000000002446 · Cited by 39
Antiepileptic drug use in seven electronic health record databases in E urope: A methodologic comparison
de Groot, M., Schuerch, M., de Vries, F., Hesse, U., Oliva, B., Gil, M., Huerta, C., Requena, G., de Abajo, F. J., Afonso, A. S. M., et al. (2014) · Epilepsia · doi:10.1111/epi.12557 · Cited by 38
Ketogenic Diets and Thermal Pain: Dissociation of Hypoalgesia, Elevated Ketones, and Lowered Glucose in Rats
Ruskin, D. N., Suter, T. A. C. S., Ross, J. L., & Masino, S. A. (2013) · Journal of Pain · doi:10.1016/j.jpain.2012.12.015 · Cited by 37
Anticonvulsant Use, Bipolar Disorder, and Risk of Fracture Among Older Adults in the Veterans Health Administration
Mezuk, B., Morden, N. E., Ganoczy, D., Post, E. P., & Kilbourne, A. M. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181bf9ebd · Cited by 36
Repurposing carbamazepine for the treatment of amyotrophic lateral sclerosis in SOD1‐G93A mouse model
Zhang, J., Zhou, Q., Chen, S., & Le, W. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12855 · Cited by 36
A review of treatment options for behavioural manifestations of clinical anxiety as a comorbidity in dogs with idiopathic epilepsy
Watson, F. C. E., Rusbridge, C., Packer, R. M. A., Casey, R., Heath, S., & Volk, H. A. (2018) · The Veterinary Journal · doi:10.1016/j.tvjl.2018.06.001 · Cited by 39
Combined carbamazepine and pregabalin therapy in a rat model of neuropathic pain
Hahm, T. S., Ahn, H. J., Ryu, S., Gwak, M. S., Choi, S. J., Kim, J. K., & Yu, J. (2012) · British Journal of Anaesthesia · doi:10.1093/bja/aes306 · Cited by 36
Role of Ventral Hippocampal GABAA and NMDA Receptors in the Anxiolytic Effect of Carbamazepine in Rats Using the Elevated Plus Maze Test
Rezvanfard, M., Zarrindast, M., & Bina, P. (2009) · Pharmacology · doi:10.1159/000256666 · Cited by 35
New antiepileptic drugs and women
Reimers, A. (2014) · Seizure · doi:10.1016/j.seizure.2014.05.004 · Cited by 34
Medication Overuse Headache
Rapoport, A. M. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00003 · Cited by 34
Anticonvulsant neuropeptides as drug leads for neurological diseases
Robertson, C. R., Flynn, S. P., White, H. S., & Bulaj, G. W. (2011) · Natural Product Reports · doi:10.1039/c0np00048e · Cited by 33
A Drosophila systems model of pentylenetetrazole induced locomotor plasticity responsive to antiepileptic drugs
Mohammad, F., Singh, P., & Sharma, A. (2009) · BMC Systems Biology · doi:10.1186/1752-0509-3-11 · Cited by 33

Authors: Johannessen Landmark, C.
Venue: CNS Drugs
Publisher: Springer Science and Business Media LLC
Published: 2008
Volume: 22
Issue: 1
Pages: 27-47
ISSN: 1172-7047 (ISSN-L)
DOI: 10.2165/00023210-200822010-00003
OpenAlex: W2195324906
Cited by: 316
References: 157
Citations by year: 2026: 5 · 2025: 4 · 2024: 11 · 2023: 15 · 2022: 9 · 2021: 7 · 2020: 5 · 2019: 17 · 2018: 10 · 2017: 10 · 2016: 22 · 2015: 15 · 2014: 18 · 2013: 27 · 2012: 28
FWCI: 4.86
Type: journal article
Language: en
Open access: closed
Locations: CNS Drugs (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Keywords: antiepileptic drugs, off-label drug use, essential tremor, neuropathic pain, migraine, anxiety disorders, schizophrenia, bipolar disorder, GABAergic neurotransmission, glutamatergic neurotransmission, ion channels, valproic acid, carbamazepine, lamotrigine, topiramate, gabapentin, pregabalin, tiagabine, mood disorders, neuroprotection, second-generation antiepileptic drugs, drug selection
MeSH terms: Anticonvulsants, Anxiety, Mental Disorders, Bipolar Disorder, Humans, Migraine Disorders, Nervous System Diseases, Pain, Schizophrenia, Essential Tremor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antiepileptic Drugs in Non-Epilepsy Disorders: Relations between Mechanisms of Action and Clinical Efficacy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks